AKR1C3 as a potential biomarker for sensitivity of T-lineage acute lymphoblastic leukaemia to the pre-prodrug PR-104

AKR1C3 作为 T 系急性淋巴细胞白血病对前药 PR-104 敏感性的潜在生物标志物

• 批准号: nhmrc : 1046173
• 负责人: Dr Hernan Carol
• 金额: $ 21.86万
• 依托单位: The University of New South Wales
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/akr1c3-potential-biomarker-pr-104/111821
• 关键词: AKR1C3; potential; biomarker; sensitivity; lineage

Multiagent chemotherapy is the most effective modality for the treatment of childhood ALL, the most common paediatric malignancy. Despite dramatic improvements in survival over the past 40 years, relapsed ALL remains one of the most common causes of death from disease in children. Therefore, innovative strategies are needed to benefit those children who respond poorly to established therapy. This application will test a novel therapy for a very aggressive subtype of childhood leukaemia.

多药化疗是治疗儿童ALL最有效的方式，ALL是最常见的儿科恶性肿瘤。尽管在过去的40年里生存率显著提高，但复发性ALL仍然是儿童疾病死亡的最常见原因之一。因此，需要创新的策略来造福那些对现有治疗反应不佳的儿童。这项应用将测试一种治疗一种非常具有侵袭性的儿童白血病亚型的新疗法。